19
Views
12
CrossRef citations to date
0
Altmetric
Original Article

ProMECE-CytaBOM vs MACOP-B in Advanced Aggressive Non-Hodgkin's Lymphoma: Long Term Results of a Multicenter Study of the Italian Lymphoma Study Group (GISL)

, , , , , , , , , , , & show all
Pages 313-320 | Received 14 Jun 1994, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Donato Mannina, Stefano Luminari, Alessandra Dondi, Giuseppe Polimeno, Luca Baldini, Caterina Stelitano, Francesco Merli, Matteo Dell'olio, Paolo G. Gobbi, Gianfranco Giglio, Elisa Barbolini, Maura Brugiatelli & Massimo Federico. (2010) Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. Leukemia & Lymphoma 51:3, pages 422-429.
Read now

Articles from other publishers (10)

Pengcheng Cai, Jinjin Hao, Dan Wang & Jiawei Xu. (2017) Comparative efficacy of different chemotherapies for non-Hodgkin lymphoma: a network-meta analysis. Oncotarget 8:53, pages 91238-91247.
Crossref
L. Lee, L. Wang & M. Crump. (2011) Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points. Annals of Oncology 22:6, pages 1392-1403.
Crossref
A. Bari, L. Marcheselli, S. Sacchi, R. Marcheselli, S. Pozzi, P. Ferri, E. Balleari, P. Musto, S. Neri, M.A. Aloe Spiriti & M.C. Cox. (2010) Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Annals of Oncology 21:7, pages 1486-1491.
Crossref
P.G. Gobbi, C. Broglia, F. Valentino, C. Mammi, M. Lombardo, F. Merli, S. Luminari, G. Polimeno, A. Riezzo, P. Lambelet, A. Rovati, G.R. Corazza & M. Federico. (2006) The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL). Annals of Oncology 17:4, pages 676-682.
Crossref
Massimo Federico, Stefano Luminari, Paolo G. Gobbi, Stefano Sacchi, Nicola Renzo, Marco Lombardo, Francesco Merli, Luca Baldini, Caterina Stelitano, Giovanni Partesotti, Giuseppe Polimeno, Antonella Montanini, Caterina Mammi & Maura Brugiatelli. (2006) The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. European Journal of Haematology 76:3, pages 217-229.
Crossref
Bertrand Coiffier. 2006. The Lymphomas. The Lymphomas 526 535 .
Li‐Yuan Bai, Muh‐Hwa Yang, Tzeon‐Jye Chiou, Jin‐Hwang Liu, Chueh‐Chuan Yen, Wei‐Shu Wang, Liang‐Tsai Hsiao, Ta‐Chung Chao & Po‐Min Chen. (2003) Non‐Hodgkin lymphoma in elderly patients. Cancer 98:6, pages 1188-1195.
Crossref
Daniele Vallisa, Raffaella Bertè, Andrea Rocca, Giuseppe Civardi, Francesco Giangregorio, Benvenuto Ferrari, Giorgio Sbolli & Luigi Cavanna. (1999) Association between hepatitis C virus and non-hodgkin’s lymphoma, and effects of viral infection on histologic subtype and clinical course. The American Journal of Medicine 106:5, pages 556-560.
Crossref
E. Montserrat, J. García‐Conde, N. Viñolas, A. López‐Guillermo, L. Hernández‐Nieto, A. Zubizarreta, J. Maldonado, A. Alcalá, M.‐V. Faura, A. Llorente, J. Bladé & M. Fontanillas. (2009) CHOP vs. ProMACE‐CytaBOM in the treatment of aggressive non‐Hodgkin's lymphomas: long‐term results of a multicenter randomized trial. European Journal of Haematology 57:5, pages 377-383.
Crossref
Angela Vecchi, Luigi Cavanna, Paolo Avanzini, Vincenzo Callea, Andrea Velardi, Nicola Albi, Pierluigi Tartoni, Laura Bensi, Paola Valentini, Rosina Longo & Stefano Sacchi. (2009) In vivo biological response following low‐dose interleukin‐2 in complete remission B‐cell non‐Hodgkin's lymphoma patients . European Journal of Haematology 57:1, pages 33-37.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.